CJC-1295 With DACUnderstand the science
What the original albumin-binding experiments established
2 numbered sourcesSource years 2005, 2026
Peptides are short amino-acid chains connected by peptide bonds. Researchers can add a chemical group to a peptide and test whether it preserves the signal while altering the compound's behavior in blood. CJC-1295 With DAC is an engineered form of growth hormone–releasing factor (GRF), also called growth hormone–releasing hormone. Its drug affinity complex (DAC) was designed to react with the blood protein albumin. [1]
The original 2005 development study provides older direct evidence for that design. Jetté and colleagues made three GRF relatives with reactive attachments. In laboratory experiments they linked each candidate to human serum albumin. The resulting conjugates were more resistant to a peptide-cleaving enzyme in that setting and stimulated growth hormone (GH) release in cultured rat pituitary cells. Those assays tested two distinct properties, chemical stability and biological activity. [1]
The researchers then studied the candidates in rats. The molecule identified as CJC-1295 produced a greater short-term GH response than the parent GRF fragment in the animal comparison. A laboratory test also detected material recognized as CJC-1295 in the part of a rat plasma sample corresponding to albumin. Together, the cell and animal results supported the idea that an albumin-linked form could continue to engage the pathway that controls GH release. [1]
The more recent 2026 equine study took the chemistry in a different direction, developing a way to detect DAC conjugates in horse blood. It measured an analytical signal, while the earlier study addressed how the attachment worked and whether the conjugate retained activity. Neither experiment measured treatment outcomes in people. The two papers show how separate assays can test the chemical design, the hormone response and the ability to identify the compound in a sample. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 1.Jetté L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology (publication 2005-04-07). (opens in a new tab)
pubmed.ncbi.nlm.nih.gov↩ Back to text
